Workup for Asymptomatic Microscopic Hematuria in a 55-Year-Old Female Non-Smoker
This 55-year-old female non-smoker with confirmed microscopic hematuria should undergo CT urography (CTU) and cystoscopy as her complete urologic evaluation. 1, 2, 3
Risk Stratification
Based on the 2025 AUA/SUFU guidelines, this patient falls into the intermediate-risk category 3:
- Age 55 years (women aged ≥60 are intermediate-risk based on age alone; however, she meets intermediate risk through other criteria)
- Non-smoker (favorable factor, but doesn't eliminate need for workup)
- Confirmed microscopic hematuria on 2 specimens (meets diagnostic threshold)
The degree of hematuria (RBCs/HPF) would further refine her risk stratification—if she has 11-25 RBC/HPF or >25 RBC/HPF, this elevates concern even without smoking history 3.
Initial Assessment Before Imaging
Before proceeding with imaging and cystoscopy, complete these evaluations 1, 4:
Laboratory testing:
- Serum creatinine to assess renal function
- Urinalysis with microscopy to evaluate for:
- Dysmorphic RBCs or red cell casts (suggests glomerular disease)
- Significant proteinuria (>1+ on dipstick)
- Pyuria or bacteriuria (suggests infection)
Clinical assessment:
- Blood pressure measurement
- Pelvic examination to exclude gynecologic causes
- Detailed history for occupational chemical exposures, analgesic abuse, pelvic irradiation, chronic UTIs
Critical decision point: If any of the following are present, concurrent nephrology referral is indicated while still proceeding with urologic evaluation 4:
- Significant proteinuria (>1000 mg/24 hours, or >500 mg/24 hours if persistent)
- Dysmorphic RBCs (>80% dysmorphic suggests glomerular origin)
- Red cell casts
- Elevated serum creatinine
Complete Urologic Workup
1. Upper Tract Imaging: CT Urography (CTU)
CTU is the gold standard imaging modality for evaluating the upper urinary tract 1, 2. This study includes:
- Unenhanced phase (detects stones)
- Nephrographic phase (evaluates renal parenchyma)
- Excretory phase (visualizes collecting systems, ureters, bladder)
CTU effectively identifies:
- Urothelial malignancies (bladder, ureter, renal pelvis)
- Renal masses
- Urolithiasis
- Hydronephrosis
- Structural abnormalities
Alternative imaging (only if CTU contraindicated due to contrast allergy or renal insufficiency) 2:
- MR urography
- Retrograde pyelograms combined with non-contrast CT or ultrasound
2. Lower Tract Evaluation: Cystoscopy
Cystoscopy is mandatory for all patients ≥35 years old with microscopic hematuria, regardless of imaging findings 2, 4. This patient at age 55 absolutely requires cystoscopy.
- Can be performed with flexible cystoscope under local anesthesia (better tolerated than rigid cystoscopy) 4
- Evaluates for bladder tumors, carcinoma in situ, urethral pathology
- Should be performed even if upper tract imaging is normal
Important caveat: The 2020 ACR guidelines note that even patients with identified benign causes on imaging should still undergo cystoscopy, as bladder lesions may be missed on CTU alone 1.
What NOT to Do
Voided urine cytology is NOT recommended as part of routine evaluation for asymptomatic microscopic hematuria 2, 5. While it detects high-grade tumors, its low sensitivity for low-grade lesions means a negative result doesn't obviate the need for cystoscopy.
Do not defer evaluation based on:
- Anticoagulant use (does not alter the need for workup) 1
- Single episode of hematuria (she already has 2 positive specimens confirming the diagnosis)
Common Pitfalls to Avoid
Assuming benign cause without complete evaluation: Even though malignancy risk is 2.6-4% in microscopic hematuria (much lower than the 30-40% with gross hematuria), missing a bladder cancer has significant mortality implications 1
Incomplete workup: Both upper tract imaging AND cystoscopy are required—one does not substitute for the other 2
Delaying evaluation for infection treatment: If UTI is suspected, treat and repeat urinalysis. Persistent hematuria after infection clearance mandates full workup 1
Gender-based under-evaluation: While women have lower bladder cancer risk than men, this patient's age (>50 years) places her at sufficient risk to warrant complete evaluation 3, 6
Follow-Up After Negative Initial Evaluation
If both CTU and cystoscopy are negative 2, 4:
- Repeat urinalysis at 6,12,24, and 36 months
- Blood pressure monitoring
- Consider repeat anatomic evaluation within 3-5 years if hematuria persists
Immediate re-evaluation required if:
- Gross hematuria develops
- Irritative voiding symptoms without infection
- Proteinuria or hypertension develops (suggests glomerular disease)
The evidence strongly supports complete evaluation in this intermediate-risk patient, as the consequences of missing urothelial malignancy (particularly bladder cancer) significantly outweigh the risks of CTU and cystoscopy 1, 2, 3.